Roivant Sciences Ltd.
$21.35B- Market cap
- $25.23B
- Debt
- +$412.94M
- Cash
- −$4.29B
Capital structure 98% equity / 2% debt · EV / Revenue 2584.97x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: ROIV stock price at premium vs AES $34.93 current versus $0.01 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AES's multiple
Implied fair value · at ROIV's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ROIV FY 2026 (ended Mar 31, 2026) · AES FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 98% equity / 2% debt · EV / Revenue 2584.97x
Capital structure 27% equity / 73% debt · EV / Revenue 3.03x · EV / EBITDA 7.78x
AES carries the larger enterprise value at $37.12B against $21.35B; AES trades on the lower EV / Revenue multiple (3.03x vs 2584.97x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ROIVANT SCIENCES LTD. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
THE AES CORPORATION · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.09x
6.92x
Net debt / EBITDA
Leverage against operating earnings
24.52x
5.57x
Cash and equivalents
Liquid reserves on the balance sheet
$4.29B
$1.56B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Revolution Medicines, Inc.
ROIV vs RVMD
INCYTE CORP
ROIV vs INCY
Sarepta Therapeutics, Inc.
ROIV vs SRPT
EXELIXIS, INC.
ROIV vs EXEL
VERTEX PHARMACEUTICALS INC / MA
ROIV vs VRTX
NRG ENERGY, INC.
ROIV vs NRG
Vistra Corp.
ROIV vs VST
Duke Energy CORP
ROIV vs DUK
CONSOLIDATED EDISON INC
ROIV vs ED
Evergy, Inc.
ROIV vs EVRG
NEXTERA ENERGY INC
ROIV vs NEE
$412.94M
$28.13B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.